A5024523248- Medical Imaging Techniques and Applications
- Dementia and Cognitive Impairment Research
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
- Cerebrospinal fluid and hydrocephalus
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Traumatic Brain Injury and Neurovascular Disturbances
- Glioma Diagnosis and Treatment
- Lanthanide and Transition Metal Complexes
- Various Chemistry Research Topics
- Radiomics and Machine Learning in Medical Imaging
- Chemistry and Chemical Engineering
- Liver Disease Diagnosis and Treatment
- Advanced MRI Techniques and Applications
- Chemical Synthesis and Reactions
- Drug Transport and Resistance Mechanisms
- History and advancements in chemistry
- Neurological and metabolic disorders
- Radiation Dose and Imaging
- Statistical Methods in Clinical Trials
- Radiopharmaceutical Chemistry and Applications
- Cerebrovascular and Carotid Artery Diseases
- Plant biochemistry and biosynthesis
- Liver Disease and Transplantation
Creative Commons
2016
Aarhus University
2016
Newcastle University
2016
Amersham Hospital
2000-2015
General Electric (Spain)
2012-2014
General Electric (Finland)
2012
General Electric (United States)
2008
GTx (United States)
2000
Washington University in St. Louis
1989-1995
In vivo imaging of brain β-amyloid, a hallmark Alzheimer disease, may assist in the clinical assessment suspected disease. To determine sensitivity and specificity positron emission tomography with flutemetamol injection labeled radioactive fluorine 18 to detect β-amyloid using neuropathologically determined neuritic plaque levels as standard truth. Open-label multicenter study that took place at dementia clinics, memory centers, hospice centers United States England from June 22, 2010,...
Clinical trials of the PET amyloid imaging agent (18)F-flutemetamol have used visual assessment to classify scans as negative or positive for brain amyloid. However, quantification provides additional information about regional and global tracer uptake may utility image over time across different centers. Using postmortem neuritic plaque density data a truth standard derive standardized value ratio (SUVR) threshold, we assessed fully automated method comparing quantitative scan...
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis Alzheimer's disease (AD), aid treatment selection for patients, trials therapeutic drugs through subject selection, and be used as an outcome measure. A recent phase III trial [18F]flutemetamol positron emission tomography (PET) in 106 end-of-life subjects demonstrated the ability to identify by comparing PET post-mortem histopathology. Post-mortem analyses a broad continuous spectrum pathology AD other dementing...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSulfineEric Block, Robert E. Penn, J. Olsen, and Paul F. SherwinCite this: Am. Chem. Soc. 1976, 98, 5, 1264–1265Publication Date (Print):March 1, 1976Publication History Published online1 May 2002Published inissue 1 March 1976https://pubs.acs.org/doi/10.1021/ja00421a038https://doi.org/10.1021/ja00421a038research-articleACS PublicationsRequest reuse permissionsArticle Views260Altmetric-Citations102LEARN ABOUT THESE METRICSArticle Views are the...
Abstract Introduction Performance of the amyloid tracer [ 18 F]flutemetamol was evaluated against three pathology standard truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” component 2012 NIA‐AA guidelines). Methods After imaging, 106 end‐of‐life patients who died underwent postmortem brain examination for plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with measures....
Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (AD), remain stable, or revert normal. Earlier progression AD among patients who were β-amyloid positive vs those negative has been previously observed. Current research now accepts that a combination of biomarkers could provide greater refinement in the assessment risk for progression.To evaluate ability flutemetamol F 18 and other assess from aMCI probable AD.In this multicenter cohort study,...
<h3>Background</h3> This study assessed the impact of DaTscan on clinical management, diagnosis, confidence diagnosis (CoD), quality life (QoL), health resource use (HRU) and safety during a 1-year follow-up in patients with clinically uncertain parkinsonian syndromes (CUPS). <h3>Methods</h3> A total 19 university hospital centres Europe USA participated this open-label, single-dose, prospective, trial CUPS who were randomised to imaging group or no-imaging (control) group. The proportion...
An electronic training programme (ETP) was developed for interpretation of images during routine clinical use the PET amyloid imaging agent [F]flutemetamol injection (VIZAMYL). This study carried out to validate ETP.Five nuclear medicine technologists (NMTs) and five readers previously inexperienced in image were required self-train using ETP pass a test participate. A total 305 then tested as validation set, following preassessment reorientation (where required) by one NMTs. Next, new set...
The efficacy of contrast-enhanced magnetic resonance imaging (MRI) for detecting and characterizing, or excluding, hepatic masses was assessed in 404 patients, following the intravenous administration mangafodipir trisodium (MnDPDP) injection, a MRI contrast agent. An initial computed tomography (CT) examination followed by unenhanced MRI, injection MnDPDP (5 μmol/kg IV), enhanced at 15 minutes post injection. Agreement radiologic diagnoses with patients' final higher combined evaluations...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTFlash vacuum pyrolysis studies. 9. Photoelectron spectra and molecular properties. 101. Synthesis thermal decomposition of 1,3-dithietane its S-oxidesE. Block, E. R. Corey, Penn, T. L. Renken, P. F. Sherwin, H. Bock, Hirabayashi, S. Mohmand, B. SoloukiCite this: J. Am. Chem. Soc. 1982, 104, 11, 3119–3130Publication Date (Print):June 1, 1982Publication History Published online1 May 2002Published inissue 1 June...
The short-term1 safety of mangafodipir trisodium (MnDPDP) injection was studied in 546 adults with known or suspected focal liver lesions. An initial contrast-enhanced computed tomography examination followed by unenhanced magnetic resonance imaging (MRI), MnDPDP (5 μmol/kg), and enhanced MRI. Adverse events were reported for 23% the patients; most mild to moderate intensity, did not require treatment, drug related. commonly adverse nausea (7%) headache (4%). incidence serious low (nine six...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXT1,3-DithietaneEric Block, Eugene R. Corey, Robert E. Penn, Terry L. Renken, and Paul F. SherwinCite this: J. Am. Chem. Soc. 1976, 98, 18, 5715–5717Publication Date (Print):September 1, 1976Publication History Published online1 May 2002Published inissue 1 September 1976https://pubs.acs.org/doi/10.1021/ja00434a061https://doi.org/10.1021/ja00434a061research-articleACS PublicationsRequest reuse permissionsArticle Views203Altmetric-Citations47LEARN...
Background and purpose This study determined the correlation between uptake of amyloid positron emission tomography ( PET ) imaging agent [ 18 F]flutemetamol amyloid‐β measured by immunohistochemical histochemical staining in a frontal cortical biopsy. Methods Fifteen patients with possible normal pressure hydrocephalus NPH previous brain biopsy obtained during intracranial monitoring underwent . Seven these also 11 C] P ittsburgh compound B i F]Flutemetamol was quantified using standardized...
To pool clinical trials of similar design to assess overall sensitivity and specificity ioflupane I123 injection (DaTSCAN or ((123)I)) detect exclude a striatal dopaminergic deficit disorder (SDDD), such as parkinsonian syndrome dementia with Lewy bodies.Pooled analysis three phase 3 one 4 trials. These four were selected because they the studies used for US new drug application Food Drug Administration (FDA).Multicentre, open-label, non-randomised.Patients either movement dementia, healthy...
Identification of risk factors is important for preventing radiocontrast-induced nephropathy (RCIN). Contrast dose and renal function have been shown in most but not all studies to be RCIN. We are investigating the ratio contrast creatinine clearance (D/CrCL) as a indicator. Theory shows that D/CrCL equals area under concentration-time curve (AUC), an accepted measure systemic exposure. This study investigated correlation between calculated experimentally measured AUC agent...
<b><i>Backgound/Objective:</i></b> To determine the level of association between uptake amyloid positron emission tomography (PET) imaging agent [<sup>18</sup>F]flutemetamol and amyloid-ß measured by immunohistochemical histochemical staining in a frontal cortical region biopsy site. <b><i>Methods:</i></b> Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective PET subsequent brain during...
PET imaging of amyloid-β (Aβ) in vivo holds promise for aiding earlier diagnosis and intervention Alzheimer's disease (AD) mild cognitive impairment. AD-like Aβ pathology is a common comorbidity patients with idiopathic normal pressure hydrocephalus (iNPH). Fifty iNPH needing ventriculo-peritoneal shunting or intracranial monitoring underwent [18F]flutemetamol before (N = 28) after 22) surgery. Cortical uptake was assessed visually by blinded reviewers, also quantitatively via standard value...
Ioflupane is an analog of cocaine that binds reversibly with high affinity to the dopamine transporter (DaT) protein, a marker for presynaptic terminals in dopaminergic nigrostriatal neurons. <sup>123</sup>I Injection also known as DaTscan or DaTSCAN (<sup>123</sup>I-ioflupane called <sup>123</sup>I-2-β-carbomethoxy-3β-(4-iodophenyl)-<i>N</i>-(3-fluoropropyl)nortropane <sup>123</sup>I-FP-CIT). The diagnostic efficacy has been described elsewhere. Here, we present comprehensive analysis...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTEffects of steroid D-ring modification on suicide inactivation and competitive inhibition aromatase by analogs androsta-1,4-diene-3,17-dionePaul F. Sherwin, Patrick C. McMullan, Douglas CoveyCite this: J. Med. Chem. 1989, 32, 3, 651–658Publication Date (Print):March 1, 1989Publication History Published online1 May 2002Published inissue 1 March 1989https://pubs.acs.org/doi/10.1021/jm00123a026https://doi.org/10.1021/jm00123a026research-articleACS...
<b><i>Background:</i></b> An accurate diagnosis is important for timely and adequate treatment in patients with clinically uncertain parkinsonian syndrome (CUPS). <b><i>Objective:</i></b> The objective of this study was to assess safety changes clinical management, quality life (QoL) at 4 12 weeks following DaTscan™ (ioflupane [<sup>123</sup>I] injection) imaging CUPS. <b><i>Methods:</i></b> This randomized,...
This Phase 2 study assessed the performance of positron emission tomography (PET) brain images made with Flutemetamol F 18 Injection in detecting β-amyloid neuritic plaques Japanese subjects. Seventy subjects (25 probable Alzheimer's disease (pAD), 20 amnestic mild cognitive impairment (aMCI), and 25 cognitively normal healthy volunteers[HVs]) underwent PET imaging after intravenous (185 MBq). Images were interpreted as or abnormal for plaque density by each five non-Japanese readers who...